Immunosuppression For Disease
Conditions
Brief summary
The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, as well as safety and tolerability of a single oral solution dose of \[14C\] Bristol-Myers Squibb (BMS)-986020 in healthy male subjects.
Detailed description
Primary purpose: Other - This study will investigate the pharmacokinetic, biotransformation, routes of elimination, and mass balance of BMS-986020 in humans. The knowledge of the routes of elimination of the drug and its metabolites is useful for evaluating the likelihood of effects of renal or hepatic impairment on the disposition of BMS-986020
Interventions
DRUG[14C] BMS-986020
Sponsors
Bristol-Myers Squibb
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy male subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Body weight of at least 50 kg (110 lbs), Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. Body mass index = weight (kg)/\[height(m)\]2 * Men, ages 18 to 50 years, inclusive * Men who are sexually active with women of childbearing potential (WOCBP) (except those with vasectomy with documented azoospermia 90 days after procedure) must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the investigational drug (4 days) plus 90 days (duration of sperm turnover) for a total of 94 days post-treatment completion
Exclusion criteria
* Any significant acute or chronic medical illness * Current or recent (within 3 months of study drug administration) gastrointestinal disease * Current or recent history of constipation or irregular bowel movements (less than once per 2 days) * Any major surgery within 4 weeks of study drug administration * Any gastrointestinal surgery that could impact upon the absorption of study drug, including cholecystectomy * History of Gilbert's Syndrome * Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only) * Blood transfusion within 4 weeks of study drug administration * Inability to tolerate oral medication * Inability to be venipunctured and/or tolerate venous access * Recent (within 6 months of study drug administration) history of smoking * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs, or clinical laboratory determinations beyond what is consistent with the target population * History of allergy to LPA1 antagonists or related compounds
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent of total administered radioactivity recovered in urine and feces (%TOTAL) | 13 Timepoints up to Day 11 |
| Apparent total body clearance (CL/F) of BMS-986020 | 19 Timepoints up to Day 8 |
| Percent of plasma BMS-986020 AUC(0-T) (%AUC(0-T)) relative to plasma TRA AUC(0-T) | 22 Timepoints up to Day 11 |
| Percent of plasma BMS-986020 AUC(INF) (%AUC(INF)) relative to plasma TRA AUC(INF) | 22 Timepoints up to Day 11 |
| Percent of total administered radioactivity excreted in urine (% UR) | 13 Timepoints up to Day 11 |
| Percent of total administered radioactivity excreted in feces (% FE) | 11 Timepoints up to Day 11 |
| Maximum observed plasma concentration (Cmax) of BMS-986020 and Total Radioactivity (TRA) | 22 Timepoints up to Day 11 |
| Time of maximum observed plasma concentration (Tmax) of BMS-986020 and TRA | 22 Timepoints up to Day 11 |
| Area under the concentration time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of BMS-986020 and TRA | 22 Timepoints up to Day 11 |
| Area under the concentration time curve from time zero to 168 hours postdose (AUC(0-168)) of BMS-986020 and TRA | 19 Timepoints up to Day 8 |
| Area under the concentration time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986020 and TRA | 22 Timepoints up to Day 11 |
| Terminal plasma half-life (T-Half) of BMS-986020 and TRA | 22 Timepoints up to Day 11 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Event (AE)s collected during the study will be reviewed for potential significance and clinical importance | Upto Day 11 |
| Clinical laboratory test results: Safety laboratory testing will be drawn at specified times | Up to Day 11 |
| Vital Signs: Blood pressure, heart rate, respiratory rate, and body temperature measurements will be assessed at specified time points | Up to Day 11 |
| Electrocardiogram (ECG): Regular ECG endpoints (heart rate, PR interval, QRS interval, and QT intervals corrected for heart rate) and investigator identified abnormalities will be assessed at the time points | Up to Day 11 |
| Physical examinations: Physical examinations will be assessed at the time points | Up to Day 11 |
Outcome results
None listed